The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients

• Status: Terminated
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to test the effectiveness of CORvalen, a medical food, to increase cellular energy sufficiently to change or modify BNP levels in congestive heart failure patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Valen Labs
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Symptomatic adults, M/F, between 18 and 80 years of age

• BNP levels equal to or greater than 300 pg/ml.

• Primary or secondary diagnosis of congestive heart failure at the time of admission (any NYHA Class)

• Diagnosis of congestive heart failure for at least 3 months

• Able to perform 6 minute hall walk

• No therapeutic pharmaceutical class changes for at least 1 month

• Provide informed consent

• A 30-day washout period must be achieved for any patient involved in a previous clinical study.

Exclusion

• Insulin dependent diabetes (Type I)

• History of obstructive valvular disease

• History of pulmonary hypertension within the last 3 months

• History of hypertrophic or alcoholic cardiomyopathy

• History of restrictive cardiomyopathy

• History of reversible cardiomyopathy

• History of non-compliance

• Pregnancy

• Current enrollment in any other clinical study